North America’s medical devices industry saw a drop of 7.8% in overall deal activity during Q1 2020, when compared to the four-quarter average, according to GlobalData’s deals database.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
A total of 247 deals worth $4.9bn were announced for the region during Q1 2020, against the last four-quarter average of 268 deals.
Of all the deal types, venture financing saw most activity in Q1 2020 with 172, representing a 69.6% share for the region.
In second place was M&A with 57 deals, followed by private equity deals with 18 transactions, respectively capturing a 23.1% and 7.3% share of the overall deal activity for the quarter.
In terms of value of deals, venture financing was the leading category in North America’s medical devices industry with $2.31bn, while M&A and private equity deals totalled $1.72bn and $870.38m, respectively.
North America medical devices industry deals in Q1 2020: Top deals
The top five medical devices deals accounted for 41.9% of the overall value during Q1 2020.
The combined value of the top five medical devices deals stood at $2.05bn, against the overall value of $4.9bn recorded for the quarter.
The top five medical devices industry deals of Q1 2020 tracked by GlobalData were:
1) Eli Lilly and’s $1.1bn acquisition of Dermira
2) The $490m private equity deal with RTI Surgical Holdings by Montagu Private Equity
3) General Catalyst Partners, HBM Healthcare Investments, Khosla Ventures, Lightspeed Management Company and SoftBank Vision Fund’s $165m venture financing of Karius
4) The $150m venture financing of Concerto HealthAI by AllianceBernstein Venture Fund, Declaration Partners, Maverick Ventures and SymphonyAI Group
5) Cormorant Asset Management, Deerfield ManagementLP, GV Management Co, Invus Opportunities, Qiming Venture Partners USA and Third Rock Ventures’ venture financing of Element Science for $145.6m.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.
